Merck & Co. and Moderna Inc. have announced that their personalized mRNA cancer vaccine intismeran prevented melanoma recurrence in a large final-stage clinical trial.
The Phase 3 trial combined intismeran with Keytruda immunotherapy in patients treated for skin cancer. Findings showed the combined treatment extended both the time before melanoma returned and the duration before tumors metastasized to other body parts.
Shares of Moderna Inc. more than doubled on Wall Street on Wednesday following the news. The result provides crucial evidence that messenger RNA technology can successfully target cancer rather than serving only as a temporary tool against infectious diseases.
Merck & Co. is a US pharmaceutical manufacturer headquartered in Rahway, New Jersey, and Moderna Inc. is a Cambridge, Massachusetts biotechnology firm known for its COVID-19 vaccine. Messenger RNA, or mRNA, instructs cells to build specific proteins, a breakthrough that helped billions of people during the coronavirus pandemic.
Clinical Trial Results and Market Response
In June, Merck and Moderna released data from an earlier five-year study tracking melanoma patients. That study showed intismeran combined with Keytruda reduced the risk of melanoma recurrence or metastasis by 49 percent compared to Keytruda treatment alone.
Keytruda has been the standard immunotherapy for melanoma since 2014. Michael Postow, chief of the melanoma service at Memorial Sloan Kettering Cancer Center in New York, said the cancer vaccine passed an already high bar and called the trial outcome a very big achievement.
Merck and Moderna issued their Phase 3 findings in a press release, withholding detailed figures on the precise scale of patient benefit. Merck plans to present full study data at an upcoming medical conference or in a peer-reviewed scientific journal.
Oncologists plan to scrutinize the full dataset to evaluate how significantly the vaccine prevents recurrence and metastasis, identify which patient groups benefit most, and determine how the shot fits into existing clinical protocols.
How Personalized mRNA Vaccines Target Tumors
Intismeran is a personalized therapeutic vaccine designed around an individual patient's tumor. Scientists decode the genetic sequence of a tumor to pinpoint specific mutations driving the malignancy.
The vaccine packages mRNA strands encoding up to 34 of those mutant proteins. By delivering genetic instructions into human cells, intismeran effectively provides immune cells with photos of the target, training them to identify and attack cancer cells over long periods.
The primary goal of cancer vaccines is relieving patients of constant fear that their disease will return aggressively. Medical researchers have explored cancer vaccines for more than a century, though numerous early-stage candidates failed over the past 20 years.
Merck and Moderna have collaborated on personalized mRNA cancer vaccines for more than a decade, starting their joint research long before COVID-19 emerged.
Evolving Treatment Protocols for Melanoma
Melanoma care has advanced since Merck and Moderna initiated the final-stage trial. Patients traditionally underwent surgery to remove skin tumors before receiving post-operative immunotherapy to suppress disease recurrence.
Recent studies demonstrate that starting immunotherapy prior to surgery yields better clinical outcomes. Postow, who served as an investigator on the trial, noted that oncologists are evaluating whether adding intismeran to post-surgery immunotherapy offers further therapeutic improvements.
Melanoma is considered an ideal target for immunotherapy because its high mutation rate makes tumor cells easier for the immune system to recognize as foreign invaders.
Expansion to Other Cancer Types
Oncologists are testing whether mRNA technology can achieve similar outcomes in other malignancies. Cancers of the lung, kidney, and certain colon types share high mutation rates, though the approach does not work for all cancers.
Researchers hope adding customized vaccines to existing therapies will boost immune responses enough to improve survival outcomes. Merck and Moderna are funding final-stage clinical trials testing mRNA vaccines for lung, bladder, and kidney cancers.
Other research teams are evaluating customized vaccines against challenging malignancies such as pancreatic cancer, showing encouraging early results in small preliminary studies.
The Phase 3 trial success comes after years of public skepticism and political debate surrounding mRNA technology. Proponents stress that developing the treatment required decades of scientific research, arguing that political rhetoric must be set aside so patients are not forced to wait for future breakthroughs.
